AVEO PHARMACEUTICALS INC (AVEO) Fundamental Analysis & Valuation

NASDAQ:AVEO • US0535883070

15 USD
0 (0%)
At close: Jan 19, 2023
15 USD
0 (0%)
After Hours: 1/19/2023, 8:09:51 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AVEO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AVEO. AVEO was compared to 520 industry peers in the Biotechnology industry. AVEO may be in some trouble as it scores bad on both profitability and health. AVEO is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. AVEO Profitability Analysis

1.1 Basic Checks

  • In the past year AVEO has reported negative net income.
  • In the past year AVEO has reported a negative cash flow from operations.
AVEO Yearly Net Income VS EBIT VS OCF VS FCFAVEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M

1.2 Ratios

  • The profitability ratios for AVEO are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVEO Yearly ROA, ROE, ROICAVEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 500 1K

1.3 Margins

  • The Gross Margin of AVEO (87.81%) is better than 91.08% of its industry peers.
  • The Profit Margin and Operating Margin are not available for AVEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVEO Yearly Profit, Operating, Gross MarginsAVEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. AVEO Health Analysis

2.1 Basic Checks

  • AVEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AVEO has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, AVEO has a worse debt to assets ratio.
AVEO Yearly Shares OutstandingAVEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
AVEO Yearly Total Debt VS Total AssetsAVEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • AVEO has an Altman-Z score of -4.48. This is a bad value and indicates that AVEO is not financially healthy and even has some risk of bankruptcy.
  • AVEO has a Altman-Z score of -4.48. This is in the lower half of the industry: AVEO underperforms 68.86% of its industry peers.
  • A Debt/Equity ratio of 0.94 indicates that AVEO is somewhat dependend on debt financing.
  • AVEO has a worse Debt to Equity ratio (0.94) than 82.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Altman-Z -4.48
ROIC/WACCN/A
WACC9.35%
AVEO Yearly LT Debt VS Equity VS FCFAVEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 2.37 indicates that AVEO has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.37, AVEO is doing worse than 78.87% of the companies in the same industry.
  • A Quick Ratio of 2.35 indicates that AVEO has no problem at all paying its short term obligations.
  • The Quick ratio of AVEO (2.35) is worse than 77.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.35
AVEO Yearly Current Assets VS Current LiabilitesAVEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. AVEO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 56.92% over the past year.
  • Looking at the last year, AVEO shows a very strong growth in Revenue. The Revenue has grown by 269.46%.
  • AVEO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 76.06% yearly.
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Sales Q2Q%100.68%

3.2 Future

  • The Earnings Per Share is expected to grow by 40.39% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 75.28% on average over the next years. This is a very strong growth
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
AVEO Yearly Revenue VS EstimatesAVEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AVEO Yearly EPS VS EstimatesAVEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

3

4. AVEO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AVEO. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 27.40, the valuation of AVEO can be described as expensive.
  • Based on the Price/Forward Earnings ratio, AVEO is valued cheaper than 96.09% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AVEO to the average of the S&P500 Index (24.79), we can say AVEO is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 27.4
AVEO Price Earnings VS Forward Price EarningsAVEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVEO Per share dataAVEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AVEO's earnings are expected to grow with 40.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.26%
EPS Next 3Y40.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVEO Dividend Analysis

5.1 Amount

  • AVEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AVEO Fundamentals: All Metrics, Ratios and Statistics

AVEO PHARMACEUTICALS INC

NASDAQ:AVEO (1/19/2023, 8:09:51 PM)

After market: 15 0 (0%)

15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-13
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.7%
Ins Owner Change0%
Market Cap521.45M
Revenue(TTM)94.32M
Net Income(TTM)-29.04M
Analysts50
Price Target15.3 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.92%
Min EPS beat(2)15.97%
Max EPS beat(2)49.87%
EPS beat(4)3
Avg EPS beat(4)18.91%
Min EPS beat(4)-18.6%
Max EPS beat(4)49.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-1.32%
Min Revenue beat(4)-3.54%
Max Revenue beat(4)1.03%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)56.59%
EPS NY rev (1m)0%
EPS NY rev (3m)10.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.4
P/S 5.53
P/FCF N/A
P/OCF N/A
P/B 18.08
P/tB 18.08
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)0.55
Fwd EY3.65%
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS2.71
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.81%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.35
Altman-Z -4.48
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Sales Q2Q%100.68%
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A
EBIT growth 1Y56.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.21%
OCF growth 3YN/A
OCF growth 5YN/A

AVEO PHARMACEUTICALS INC / AVEO FAQ

What is the fundamental rating for AVEO stock?

ChartMill assigns a fundamental rating of 3 / 10 to AVEO.


What is the valuation status for AVEO stock?

ChartMill assigns a valuation rating of 3 / 10 to AVEO PHARMACEUTICALS INC (AVEO). This can be considered as Overvalued.


How profitable is AVEO PHARMACEUTICALS INC (AVEO) stock?

AVEO PHARMACEUTICALS INC (AVEO) has a profitability rating of 1 / 10.


What is the expected EPS growth for AVEO PHARMACEUTICALS INC (AVEO) stock?

The Earnings per Share (EPS) of AVEO PHARMACEUTICALS INC (AVEO) is expected to grow by 59.87% in the next year.